(IMMX) Immix Biopharma - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 541m USD | Total Return: 264.3% in 12m
Avg Turnover: 6.49M
Warnings
Share dilution 28.9% YoY
Altman Z'' -12.98 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader
Immix Biopharma, Inc. (IMMX) is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies. Headquartered in Los Angeles and operating across the United States and Australia, the firm primarily targets light chain (AL) amyloidosis and various immune-mediated diseases. Its lead therapeutic candidate, NXC-201, is currently being evaluated for patients with relapsed or refractory AL amyloidosis.
The company operates within the high-risk, high-reward biotechnology sector, where business models typically rely on heavy research and development spending and the achievement of regulatory milestones before generating product revenue. CAR-T therapy represents a specialized segment of immunotherapy that involves engineering a patients own T-cells to recognize and attack specific disease markers. For a deeper look into these technical milestones, consult ValueRay for additional data. Immix Biopharma was incorporated in 2012 and continues to advance its clinical pipeline toward potential commercialization.
- NXC-201 clinical trial outcomes drive pivotal data readouts and valuation shifts
- FDA regulatory milestones for AL Amyloidosis treatment path impact share price
- Capital requirements for cell therapy manufacturing expansion influence future dilution risk
- Competitive landscape in autoimmune and amyloidosis markets dictates long-term commercial viability
- Strategic partnerships or licensing agreements provide necessary non-dilutive funding sources
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.34 > 0.02 and ΔFCF/TA 33.15 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.33 > 3% & CFO -32.1m > Net Income -35.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (38.3m) vs 12m ago 28.90% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.48%; Δ -0.48% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.85 (Total Current Assets 92.3m - Total Current Liabilities 10.5m) / Total Assets 95.8m |
| B: -1.20 (Retained Earnings -114.5m / Total Assets 95.8m) |
| C: -0.62 (EBIT TTM -36.0m / Avg Total Assets 57.9m) |
| D: -9.99 (Book Value of Equity -114.4m / Total Liabilities 11.5m) |
| Altman-Z'' = -12.98 = D |
As of May 24, 2026, the stock is trading at USD 8.67 with a total of 5,930,257 shares traded.
Over the past week, the price has changed by -11.67%,
over one month by -13.75%,
over three months by +7.47% and
over the past year by +264.32%.
Immix Biopharma has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy IMMX.
- StrongBuy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17.6 | 102.5% |
Revenue TTM = 0.0 USD
EBIT TTM = -36.0m USD
EBITDA TTM = -35.6m USD
Long Term Debt = 912k USD (estimated: total debt 1.04m - short term 125k)
Short Term Debt = 125k USD (from shortTermDebt, last quarter)
Debt = 1.04m USD (from shortLongTermDebtTotal, last quarter) (leases 1.07m already included)
Net Debt = -89.5m USD (calculated: Debt 1.04m - CCE 90.6m)
Enterprise Value = 451.3m USD (540.8m + Debt 1.04m - CCE 90.6m)
Interest Coverage Ratio = unknown (Ebit TTM -36.0m / Interest Expense TTM 0.0)
EV/FCF = -13.77x (Enterprise Value 451.3m / FCF TTM -32.8m)
FCF Yield = -7.26% (FCF TTM -32.8m / Enterprise Value 451.3m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 365k) / Revenue TTM)
Tobins Q-Ratio = 4.71 (Enterprise Value 451.3m / Total Assets 95.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.04m)
Taxrate = 21.0% (US default 21%)
NOPAT = -28.4m (EBIT -36.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.76 (Total Current Assets 92.3m / Total Current Liabilities 10.5m)
Debt / Equity = 0.01 (Debt 1.04m / totalStockholderEquity, last quarter 84.4m)
Debt / EBITDA = 2.52 (negative EBITDA) (Net Debt -89.5m / EBITDA -35.6m)
Debt / FCF = 2.73 (negative FCF - burning cash) (Net Debt -89.5m / FCF TTM -32.8m)
Total Stockholder Equity = 47.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -60.47% (Net Income -35.0m / Total Assets 95.8m)
RoE = -21.55% (Net Income TTM -35.0m / Total Stockholder Equity 162.3m)
RoCE = -22.05% (EBIT -36.0m / Capital Employed (Equity 162.3m + L.T.Debt 912k))
RoIC = 1.27k% (out of range, set to none) (NOPAT -28.4m / Invested Capital -2.23m)
WACC = 10.40% (E(540.8m)/V(541.9m) * Re(10.42%) + D(1.04m)/V(541.9m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.89 | Cagr: 33.69%
[DCF] Fair Price = unknown (Cash Flow -32.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.38 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.20 | Chg30d=+2.44% | Revisions=-20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.20 | Chg30d=+2.02% | Revisions=-20% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.79 | Chg30d=-2.60% | Revisions=-20% | GrowthEPS=+11.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.71 | Chg30d=+2.41% | Revisions=N/A | GrowthEPS=+10.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -20%